Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-2 Study)

NCT04036292 is registered in ClinicalTrials.gov with Oyster Point Pharma, Inc. as lead sponsor.

NCT NCT04036292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04036292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-2 Study)
Lead sponsor
Oyster Point Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 23, 2019
Completion date
February 5, 2021
Enrollment
758 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease (ded)